Indian CNS Therapeutics Market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.
Indian market for CNS Therapeutics is driven by the urgent need to address the unmet medical needs of neurological disorders. The incidence of central nervous system (CNS) tumours in India ranges from 5 to 10 per 100,000 population with an increasing trend and accounts for 2% of malignancies. Government of India has introduced National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular diseases & Stroke with the objectives of prevention, screening, early detection, diagnosis and treatment including palliative care in end stage for the major non communicable diseases. 40% of all cancers spread to brain. Brain and central nervous system tumours are also the second most common cancers in children, accounts for about 26% of childhood cancers.
Strong opportunities for CNS focused drugs exists and compounding this need is the rapidly aging population and a parallel rise in Parkinson’s, Alzheimer’s, pain manifestations, cerebrovascular disorders, stroke, seizures, cognitive and memory disorders. The growing focus on healthcare cost containment and rationalization and legislation of policies that encourage physician prescription of generic drugs will encourage sales of generic CNS medications. The central nervous system therapeutic market is anticipated to grow due to the key driving factors such as increasing prevalence of neurological disorders, increase in adoption of new- generation drugs and growing awareness regarding psychiatric disorders, rapidly disease cases is likely to grow the market during the forecast period.